Contineum Therapeutics, Inc. (CTNM)
9.86
+0.08
(+0.82%)
USD |
NASDAQ |
Nov 13, 16:00
9.885
+0.02
(+0.25%)
After-Hours: 19:59
Contineum Therapeutics Net Income (Quarterly) : -18.70M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -18.70M |
| June 30, 2026 | -15.15M |
| March 31, 2026 | -14.46M |
| December 31, 2025 | -15.16M |
| September 30, 2025 | -12.79M |
| June 30, 2025 | -16.04M |
| March 31, 2025 | -15.99M |
| December 31, 2024 | -14.56M |
| Date | Value |
|---|---|
| September 30, 2024 | -10.27M |
| June 30, 2024 | -9.009M |
| March 31, 2024 | -8.417M |
| December 31, 2023 | -7.769M |
| September 30, 2023 | -6.251M |
| June 30, 2023 | 41.56M |
| March 31, 2023 | -4.824M |
| December 31, 2022 | -7.512M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -3.164M |
| CNBX Pharmaceuticals, Inc. | -0.1542M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -53.90M |
| Fulcrum Therapeutics, Inc. | -10.94M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 18.70M |
| EPS Diluted (Quarterly) | -0.487 |
| Enterprise Value | 148.78M |
| Earnings Yield | -17.95% |
| Normalized Earnings Yield | -17.95 |